Antispasticity medications: Uses and limitations of enteral therapy

American Journal of Physical Medicine and Rehabilitation

Volumn 83, Issue 10 SUPPL., 2004, Pages

  Zafonte, Ross ^a,c   Lombard, Lisa ^a   Elovic, Elie ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

Antispasticity Medications; Enternal Therapy; Spasticity

Indexed keywords

4 AMINOPYRIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CANNABIS; CLONAZEPAM; CLONIDINE; CYPROHEPTADINE; DANTROLENE; DIAZEPAM; DRONABINOL; GABAPENTIN; GLYCINE; IVERMECTIN; NABILONE; NORADRENALIN; PIRACETAM; PROGABIDE; TETRAHYDROCANNABINOL; THREONINE; TIZANIDINE;

ASTHENIA; ATAXIA; BRADYCARDIA; CLINICAL TRIAL; CLONUS; COGNITIVE DEFECT; CONFERENCE PAPER; DIZZINESS; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FATIGUE; GAIT; HUMAN; HYPOTENSION; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MEDICAL LITERATURE; MEMORY DISORDER; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; ORTHOSTATIC HYPERTENSION; PATIENT CARE; PRACTICE GUIDELINE; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STROKE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VASOSPASM; XEROSTOMIA;

4-AMINOPYRIDINE; ACETIC ACIDS; ADRENERGIC ALPHA-AGONISTS; AMINES; BACLOFEN; BENZODIAZEPINES; CYCLOHEXANECARBOXYLIC ACIDS; CYPROHEPTADINE; DANTROLENE; GAMMA-AMINOBUTYRIC ACID; GLYCINE; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEUROPROTECTIVE AGENTS; PIRACETAM; SEROTONIN ANTAGONISTS; TETRAHYDROCANNABINOL;

EID: 4644372328     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PHM.0000141132.48673.FA     Document Type: Conference Paper

References (120)

1. Ward A, Chaffamn M, Sorkin E: Dantrolene: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, neuroleptic malignant syndrome and muscle spasticity. Drugs 1986; 32:130-8
2. Langeron O, Coirault C, Fratea S, et al: The effects of dantrolene on the contraction, relaxation, and energetics of the diaphragm muscle. Anesth Analg 1999;89: 466-71
3. Elovic E: Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:793-816
4. Wuis E, Vree T, Van Der Kleijn E: Pharmacokinetics of intravenously administered dantrolene and its 5-hydroxy metabolite in dogs. Int J Clin Pharmacol Res 1990;10:203-10
5. Nakayama R, Yano T, Ushijima K, et al: Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. Anesthesiology 2002;96:705-10
6. Popescu BO, Oprica M, Sajin M, et al: Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. J Cell Mol Med 2002;6:555-69
7. Steinberg F, Ferguson K: Effect of dantrolene sodium on spasticity associated with hemiplegia. J Am Geriatr Soc 1975;23:70-3
8. Meyler W, Mols-Thurkow H, Wesseling H: Relationship between plasma concentration and effect of dantrolene sodium in man. Eur J Clin Pharmacol 1979;16: 203-9
9. Katrak P, Cole A, Pulos C, et al: Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after cerebrovascular accident: A randomized double blind trial. Arch Phys Med Rehabil 1992;73:4-9
10. Knutsson E, Martensson A: Action of dantrolene sodium in spasticity with low dependence on fusimotor drive. J Neurol Sci 1976;29:195-212
11. Joynt R: Dantrolene sodium: Long term effects in patients with muscle spasticity. Arch Phys Med Rehabil 1976;57: 212-7
12. Schmidt R, Lee R, Spehlmann R: Treatment of spasticity in multiple sclerosis: Comparison of dantrolene sodium and diazepam. Trans Am Neurol Assoc 1975;100:235-7
13. Haslam R, Walcher J, Lietman PS: Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55: 384-7
14. Krach L: Pharmacotherapy of spasticity: Oral medications and intrathecal baclofen. J Child Neurol 2001;16:31
15. Glass A, Hannah A: A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 1974; 12:170-6
16. Ketel W, Kolb M: Long term treatment with dantrolene sodium of stroke patients with spasticity limiting return of function. Curr Med Res Opin 1984;9: 161-9
17. Chyatte S, Birdsong J, Bergaman B: The effects of dantrolene sodium on spasv ticity and motor performance in hemiplegia. South Med J 1971;64:180-9
18. Durham JA, Gandolfi AJ, Bentley JB: Hepatotoxicological evaluation of dantrolene sodium. Drug Chem Toxicol 1984;7:23-40
19. Chan C: Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-32
20. Chou TC, Li CY: Inhibitory mechanisms of dantrolene on platelet aggregation. Thromb Res 1999;96:299-307
21. Nogen A: Medical treatment for spasticity in children with cerebral palsy. Child Brain 1976;2:304-8
22. Felz MW, Haviland-Foley DJ: Eosinophilic pleural effusion due to dantrolene: Resolution with steroid therapy. South Med J 2001;94:502-4
23. Dohen F, Montagne V, Lelieur E: Dantrolene-induced pleurisy: A case report. Rev Pneumol Clin 200;56:261-3
24. Petusevsky ML, Faling LJ, Rocklin RE, et al: Pleuropericardial reaction to treatment with dantrolene. JAMA 1979; 242:2772-4
25. Pembroke A, Saxena S, Kataria M, et al: Acne induced by dantrolene. Br J Dermatol 1981;104:465-8
26. Taricco M, Adone R, Pagliacci C, et al: Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000;2: CD001131
27. Basmajian J, Yucel V: Effects of GABA-derivative (BA-34647) on spasticity: Preliminary report of a double-blind cross-over study. Am J Phys Med Rehabil 1974;53: 223-8
28. Pedersen E, Arlen-Soborg P, Grynderup V, et al: GABA derivative in spasticity. Acta Neurol Scand 1970;46:257-64
29. Nielsen JF, Anderson JB, Sinkjaer T: Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. Mult Scler 2000;6:105-14
30. Nielsen JF, Sinkjaer T: Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. Muscle Nerve 2000;23:98-105
31. Orsnes G, Sorensen P, Larsen T, et al: Effect of baclofen on gait in spastic MS patients Acta Neurol Scand 2000;101: 244-8
32. Gracies J, Nance P, Elovic E: Traditional pharmacological treatments for spasticity: Part 2. General and regional treatments. Muscle Nerve Suppl 1997;6: S92-120
33. Mila P, Jackson A: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398
34. Goldstein LB: Neuropharmacology of TBI-induced plasticity. Brain Inj 2003;17: 685-94
35. Wallace A, Kline A, Montanez S, et al: Impact of the novel anticonvulsant vigabatrin on functional recovery following brain lesion. Restor Neurol Neurosci 199; 14:35-45
36. Sandyk R, Gillman M: Baclofen-induced memory impairment. Clin Neuropharmacol 1985;8:294-5
37. Castellano C, Brioni J, Nagahara A, et al: Post-training systemic and intraamygdala administration of the GABA-B agonist baclofen impairs retention. Behav Neural Biol 1989;52:170-9
38. Terrence C, Fromm G, Roussan M: Baclofen: Its effect on seizure frequency. Arch Neurol 1983;40:28-9
39. Zafonte R, Elovic E: Spasticity and abnormalities of muscle tone, in Grabois M, Garrsion S, Hart K (eds): Physical Medicine and Rehabilitation: The Complete Approach. Maiden, MA, Blackwell Science, 2000, pp 848-58
40. Comer S, Haney M, Fischman M: Cyproheptadine produced modest increase in total caloric intake by humans. Physiol Behav 1997;62:831-9
41. Nance PW: Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:889-905
42. Horowitz B, Mullins M: Cyproheptadine for serotonin syndrome in an accidental pediatric ingestion. Pediatr Emerg Care 1999;15:325-9
43. White S, Neuman R: Pharmacological antagonism of facilitatory but not inhibitory effects of serotonin and norepinephrine on excitability of spinal motor neurons. Neuropharmacology 1983;22: 489-92
44. Barbeau H, Richards C, Bedard P: Action of cyproheptadine in spastic paraparetic patients. J Neurol Neurosurg Psychiatry 1982;45:923-6
45. Meythaler J, Roper J, Brunner R: Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 2003; 84:638-42
46. Naftchi NE, Schlosser W, Horst WD: Correlation of changes in the GABA-ergic system with the development of spasticity in paraplegic cats. Adv Exp Med Biol 1979;123:431-50
47. Wilson LA, McKechnie AA: Oral diazepam in the treatment of spasticity in paraplegia: A double-blind trial and subsequent impressions. Scott Med J 1966; 11:46-51
48. Corbett M, Frankel HL, Michaelis L: A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972;10:19-22
49. Griffiths AP, Sylvester PE: Clinical trial of diazepam in adult cerebral palsy. Ann Phys Med 1964;suppl:25-29
50. Bes A, Eyssette M, Pierrot-Deseilligny E, et al: A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709-18
51. Roussan M, Terrence C, Fromm G: Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1985;4:278-84
52. From A, Heltberg A: A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975;51:158-66
53. Agrawal P: Diazepam addiction: A case report. Can Psychiatr Assoc J 1978; 23:35-7
54. Consroe P: Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998;5(6 Pt B):534-51
55. Baker D, Pryce G, Croxford JL, et al: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-7
56. Meinck HM, Schonle PW, Conrad B: Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236:120-2
57. Consroe P, Musty R, Rein J, et al: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8
58. Malec J, Harvey RF, Cayner JJ: Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 1982;63: 116-8
59. Ungerleider JT, Andyrsiak T, Fairbanks L, et al: Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50
60. Killestein J, Hoogervorst EL, Reif M, et al: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-7
61. Petro DJ, Ellenberger C Jr: Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981;21(8-9 suppl):413S-6S
62. Zajicek J, Fox P, Sanders H, et al: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
63. Kogel RW, Johnson PB, Chintam R, et al: Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. Am J Ther 1995;2:799-805
64. Greenberg HS, Werness SA, Pugh JE, et al: Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55:324-8
65. Simpson RK Jr, Robertson CS, Goodman JC: Glycine: An important potential component of spinal shock. Neurochem Res 1993;18:887-92
66. Mulhardt C, Fischer M, Gass P, et al: The spastic mouse: Aberrant splicing of glycine receptor beta subunit mRNA caused by intronic insertion of L1 element. Neuron 1994;13:1003-15
67. A receptors in the pathogenesis of spinal myoclonus: In vitro studies in the isolated neonatal rodent spinal cord. Neurology 1995;45:1883-92
68. Simpson RK Jr, Gondo M, Robertson CS, et al: The influence of glycine and related compounds on spinal cord injury-induced spasticity. Neurochem Res 1995; 20:1203-10
69. Simpson RK Jr, Robertson CS, Goodman JC: The role of glycine in spinal shock. J Spinal Cord Med 1996;19:215-24
70. Simpson RK Jr, Robertson CS, Goodman JC: Segmental recovery of amino acid neurotransmitters during posterior epidural stimulation after spinal cord injury. J Am Paraplegia Soc 1993;16:34-41
71. Stern P, Bokonjic R: Glycine therapy in 7 cases of spasticity: A pilot study. Pharmacology 1974;12:117-9
72. Barbeau A, Roy M, Chouza C: Pilot study of threonine supplementation in human spasticity. Can J Neurol Sci 1982; 9:141-5
73. Growdon JH, Nader TM, Schoenfeld J, et al: L-threonine in the treatment of spasticity. Clin Neuropharmacol 1991;14: 403-12
74. Hauser SL, Doolittle TH, Lopez-Bresnahan M, et al: An antispasticity effect of threonine in multiple sclerosis. Arch Neurol 1992;49:923-6
75. Lee A, Patterson V: A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993; 88:334-8
76. Heckman CJ: Alterations in synaptic input to motoneurons during partial spinal cord injury. Med Sci Sports Exerc 1994;26:1480-90
77. Tremblay LE, Bedard PJ: Effect of clonidine on motoneuron excitability in spinalized rats. Neuropharmacology 1986;25:41-6
78. Maynard FM: Early clinical experience with clonidine in spinal spasticity. Paraplegia 1986;24:175-82
79. Nance PW, Shears AH, Nance DM: Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;27:296-301
80. Nance PW: A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994;17:150-6
81. Sandford PR, Spengler SE, Sawasky KB: Clonidine in the treatment of brain-stem spasticity: Case report. Am J Phys Med Rehabil 1992;71:301-3
82. Dall JT, Harmon RL, Quinn CM: Use of clonidine for treatment of spasticity arising from various forms of brain injury: A case series. Brain Inj 1996;10: 453-8
83. Donovan WH, Carter RE, Rossi CD, et al: Clonidine effect on spasticity: A clinical trial. Arch Phys Med Rehabil 1988; 69(3 pt 1):193-4
84. Middleton JW, Siddall PJ, Walker S, et al: Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: A case study. Arch Phys Med Rehabil 1996;77:824-6
85. Naftchi NE: Functional restoration of the traumatically injured spinal cord in cats by clonidine. Science 1982;217: 1042-4
86. Norman KE, Pepin A, Barbeau H: Effects of drugs on walking after spinal cord injury. Spinal Cord 1998;36:699-715
87. Feeney DM, Westerberg VS: Norepinephrine and brain damage: Alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol 1990;44:233-52
88. Goldstein LB: Common drugs may influence motor recovery after stroke: The Sygen in Acute Stroke Study Investigators. Neurology 1995;45:865-71
89. Weingarden SI, Belen JG: Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil 1992;73:876-7
90. Yablon SA, Sipski ML: Effect of transdermal clonidine on spinal spasticity: A case series. Am J Phys Med Rehabil 1993; 72:154-7
91. Skoog B: A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats. Acta Physiol Scand 1996;156:81-90
92. Emre M, Leslie GC, Muir C, et al: Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry 1994;57:1355-9
93. Nance PW, Sheremata WA, Lynch SG, et al: Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54:731-6
94. Medici M, Pebet M, Ciblis D: A double-blind, long-term study of tizanidine (Sirdalud) in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989; 11:398-407
95. Meythaler JM, Guin-Renfroe S, Johnson A, et al: Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-63
96. Wagstaff AJ, Bryson HM: Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-52
97. Milanov I, Georgiev D: Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994;89:274-9
98. Gelber DA, Good DC, Dromerick A, et al: Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32: 1841-6
99. Groves L, Shellenberger MK, Davis CS: Tizanidine treatment of spasticity: A meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15:241-51
100. Wallace JD: Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44(11 suppl 9):S60-8
101. Smith KJ, Felts PA, John GR: Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123(pt 1):171-84
102. Wolfe DL, Hayes KC, Hsieh JT, et al: Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: A double-blinded, placebo-controlled crossover trial. J Neurotrauma 2001;18:757-71
103. Solari A, Uitdehaag B, Giuliani G, et al: Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2003;2:CD001330
104. Hansebout RR, Blight AR, Fawcett S, et al: 4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;10:1-18
105. Donovan WH, Halter JA, Graves DE, et al: Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000;38:7-15
106. Potter PJ, Hayes KC, Hsieh JT, et al: Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases. Spinal Cord 1998;36:147-55
107. Potter PJ, Hayes KC, Segal JL, et al: Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998;15:837-49
108. Segal JL, Brunnemann SR: 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy 1997;17:415-23
109. Segal JL, Pathak MS, Hernandez JP, et al: Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial. Pharmacotherapy 1999;19:713-23
110. Grijalva I, Guizar-Sahagun G, Castaneda-Hernandez G, et al: Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: A randomized, double-blind, placebo-controlled trial. Pharmacotherapy 2003;23:823-34
111. Mueller ME, Gruenthal M, Olson WL, et al: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997;78: 521-4
112. Dunevsky A, Perel AB: Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998;77:451-4
113. Gruenthal M, Mueller M, Olson WL, et al: Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35:686-9
114. Priebe MM, Sherwood AM, Graves DE, et al: Effectiveness of gabapentin in controlling spasticity: A quantitative study. Spinal Cord 1997;35:171-5
115. Childers MK, Holland D: Psychomotor agitation following gabapentin use in brain injury. Brain Inj 1997;11:537-40
116. Cutter NC, Scott DD, Johnson JC, et al: Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81:164-9
117. Maritz N, Muller F, Pompe van Meedervoot H: Piracetam in the management of spasticity in cerebral palsy. S Afr Med J 1978;53:889-95
118. Rudick R, Brenton D, Krall R: The GABA-agonist progabide for spasticity in multiple sclerosis Arch Neurol 1987;44: 1033-9
119. Mondrup K, Petersen E: The clinical effect of the GABA-agonist progabide on spasticity. Acta Neurol Scand 1984;69: 200-4
120. Costa J, Diazgrandados J: Invermectin for spasticity in spinal cord injury. Lancet 1994;343:739-42